Seminar in Medicine, 30.11.2017, Prof. Dr. Fabien Gosselet

Author: KUSOM
Time: 12:00
Location: ENG 208



Thursday, November 30th, 2017



Speaker        : Prof. Dr. Fabien Gosselet / Director of the Blood-brain barrier Laboratory, University of Artois (Lens, France)
Title             : Use of in vitro models to investigate blood-brain barrier physiology and its roles in Alzheimer’s disease
Time            : 12.00 
Place            : ENG 208           


Use of in vitro models to investigate blood-brain barrier physiology and its roles in Alzheimer’s disease


The blood-brain barrier (BBB) is located at the brain microvessel level and isolates the brain from the whole body, thus restricting molecule and cell exchanges between cerebral and peripheral compartments. In order to better decipher and understand the BBB physiology and development, and to investigate transport mechanism and toxicity of neuropharmaceuticals, several in vitro BBB models have been developed using animal or human cells, primary or immortalized cells. The first aim of this talk is to explain the major criteria required for a pertinent in vitro BBB model and to briefly expose the different models currently available in my laboratory with their characteristics. In the second part of my talk, I will describe how we use these in vitro BBB models to better characterize the role of the BBB in Alzheimer’s disease (AD). This disease is characterized by an altered brain cholesterol homeostasis. For a long time, the BBB was basically considered as a barrier isolating the brain from circulating cholesterol, however, several lines of evidence now suggest that the BBB strictly regulates the exchanges of sterol between the brain and the peripheral circulation. Oxysterols, synthesized by neurons or by peripheral cells, cross the BBB easily and modulate the expression of several enzymes, receptors, and transporters which are involved not only in cholesterol metabolism but also in other brain functions. This talk deals with the way oxysterols impact BBB cells. These perspectives open new routes for designing certain therapeutical approaches that target the BBB so that the onset and/or progression of brain diseases such as AD may be modulated.